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Summary
The “neurofi bromatoses” (NFs) are a group of distinct genetic disorders that are commonly associated with the 
 appearance of nerve tumours. They include NF1, NF2 and schwannomatosis, with the NF1 or von Recklinghausen disease 
being the most common form. All these disorders are dominantly inherited with a high rate of new mutation and variable 
expression. It is typically regarded as a cancer predisposition syndrome; however the most common complication of NF1 in 
childhood is impairment in academic achievement and cognition with att entional, executive, language and visuospatial 
functions frequently aff ected. This paper therefore, att empts to emphasize the existence and importance of psychological 
disorders and diffi  culties in people with NF1. Early detection of existing psychiatric disorders in NF1 patients opens the 
possibility of early treatment and bett er quality of life. In this study an overview of the latest fi ndings regarding mental 
disorders in NF1 patients is given. The majority of studies to date have based their investigation on cognitive impairments 
whose frequency is high in NF1 patients. Other investigations describe the problems of socialization, quality of life and the 
possibility of medical treatment. It is important that specialists of diff erent areas of expertise have a clear overview of all 
mental disorders and diffi  culties that may occur in people aff ected by this disease. The importance of a multidisciplinary 
approach to treatment is also emphasized, which will lead to more successful forms of treatment and improve the quality of 
life of patients with NF1.
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PSIHIJATRIJSKI POREMEĆAJI U BOLESNIKA S NEUROFIBROMATOZOM
Sažetak
Neurofi bromatoze (NF) su skup različitih genetskih poremećaja kojima je zajednička karakteristika pojava tumora 
živčanog sustava. Razlikuju se tri oblika bolesti: NF1, NF2 i švanomatoza, a najčešći oblik je NF1 ili von Recklinghausenova 
bolest. Neurofi bromatoze se nasljeđuju autosomno dominantno s visokom stopom novih mutacija i varijabilnom ekspresi-
jom. Iako se NF1 smatra bolešću s povećanim rizikom za razvoj tumora, njena najčešća komplikacija u djetinjstvu je ošte-
ćenje akademskog postignuća i spoznaje, pri čemu su često pogođene pozornost, izvršne, jezične i vizualno-prostorne funk-
cije. Stoga se ovim radom željelo ukazati na važnost psihičkih poremećaja i poteškoća kod osoba oboljelih od NF1. Njihovo 
rano uočavanje otvara mogućnost ranijeg početka liječenja, a time bolje kvalitete života bolesnika. U radu je dan pregled 
novih spoznaja o psihičkim poremećajima koji se mogu javiti kod oboljelih od NF. Prikazana su istraživanja koja su poku-
šala objasniti pojedine psihičke funkcije kod oboljelih osoba. Najveći broj istraživanja bavi se kognitivnim poteškoćama čija 
je učestalost kod oboljelih od NF1 vrlo visoka. Ostala istraživanja opisuju probleme socijalizacije i kvalitete života te moguć-
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nosti medikamentoznog liječenja psihičkih poremećaja. Važno je i korisno da stručnjaci različitih specijalnosti imaju šire 
znanje o psihičkim poremećajima i poteškoćama koje se mogu javiti kod osoba oboljelih od NF1. Također se ovim radom 
željela naglasiti važnost multidisciplinarnog pristupa kod liječenja NF čime će se postići i uspješnije liječenje i poboljšati 
kvaliteta života bolesnika.
KLJUČNE RIJEČI: neurofi bromatoza, psihički poremećaji, kognitivne poteškoće, ADHD, autizam
INTRODUCTION
The “neurofi bromatoses” (NFs) are a group 
of distinct genetic disorders that are commonly as-
sociated with the appearance of nerve tumours. 
They include NF1, NF2 and schwannomatosis, 
with the NF1 or von Recklinghausen disease be-
ing the most common form. All these disorders 
are dominantly inherited with a high rate of new 
mutation and variable expression. NF1 has an ef-
fect on multiple systems of the body. The main 
NF1-associated tumour is the neurofi broma. NF2 
includes schwannomas of multiple cranial and 
spinal nerves, particularly the vestibular nerve, as 
well as other tumours such as meningiomas and 
ependymomas. The schwannomatosis phenotype 
is limited to multiple schwannomas and usually 
accompanied with pain. The genes that underlie 
each of the disorders that are known include NF1 
for neurofi bromatosis type 1 which resides on 
chromosome 17q11.2, NF2 for neurofi bromatosis 
type 2, and INI1/SMARCB1 for schwannomatosis 
(1). Diagnostic features of NF1 include alterations 
in skin pigmentation (café au lait spots, skinfold 
freckling), Lisch nodules and the above mentioned 
nervous system tumours (neurofi bromas and op-
tic pathway gliomas). Additionally, clinical mani-
festations include bone dysplasia, learning dis-
abilities and an increased risk of malignancy (2). 
Birth incidence of NF1 is 1 in 2700. It is typically 
regarded as a cancer predisposition syndrome, 
however the most common complication of NF1 
in childhood is impairment in academic achieve-
ment and cognition, with att entional, executive, 
language and visuospatial functions frequently 
aff ected (3-6). However, in patients with NF very 
litt le is known about these type of disorders. The 
intention of this paper is to emphasize the exis-
tence and importance of psychological disorders 
and diffi  culties in people with NF1. It is important 
that specialists of diff erent areas of expertise have 
a clear overview of all mental disorders and diffi  -
culties in people aff ected by this disease. The im-
portance of a multidisciplinary approach to treat-
ment is also emphasized, which will further lead 
to more successful forms of treatment and im-
prove the quality of life of patients with NF1.
Att ention defi cit hyperactivity disorder 
and neurofi bromatosis type 1
Hyperactivity or hyperkinesis disorder (at-
tention defi cit hyperactivity disorder - ADHD) is 
defi ned as a trias involving hyperkinesia, att en-
tion defi cit and impulsivity (7). The incidence of 
ADHD in patients with NF1 ranges between 33% 
and 49.5% and is equally common in both sexes 
(8). According to the Centre for Disease Control 
and Prevention (CDCP) report from 2011–2013, 
the percentage of ADHD diagnosed among chil-
dren between the ages of 4 to 17 was 11.5%, and by 
sex: 13.3% in males and 5.6% in females (2). The 
ADHD-like symptoms in NF1 appear to involve 
complex impairments in cognitive processes, vi-
suospatial function and executive function that 
may operate through mechanisms that probably 
diff er from those responsible for ADHD in indi-
viduals without NF1 (3,9). Researchers have sug-
gested that impaired reactivity to visual signals 
may play a role (4). In the research conducted by 
Sanchez-Marco et al (9), 56 patients with NF1 were 
included. Twenty three patients (41%) were diag-
nosed with ADHD with the mean age at ADHD 
diagnosis being 7.53 ± 2.46 years. School-age chil-
dren with ADHD represented 48.8% of cases. All 
but one of the children received treatment and the 
mean duration of treatment was 3.85 ± 3.04 years. 
Positive eff ects were reported by eleven patients 
with a moderate response in eight patients. The 
research results confi rm the high prevalence of 
ADHD in patients with NF1. Early diagnosis and 
treatment of ADHD in patients with NF1 is high-
lighted and the results reveal good patient adher-
ence and medical treatment outcomes in most pa-
tients if the diagnosis and treatment are timely 
initiated (9). Several studies suggest that the cog-
nitive, motor, learning, and social problems often 
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identifi ed in patients with NF1 are not a distinct 
comorbidity of the disease but rather a direct con-
sequence of NF1 pathology (10). Koth et al (11) 
compared the ADHD status of children with NF1 
to that of their healthy siblings and biological par-
ents and found a signifi cant connection between 
NF1 and ADHD, suggesting that ADHD occurs as 
a component of the underlying disease.
Cohen et al (12) investigated whether the use 
of MOXO visual- and vocal-distractors-based con-
tinuous performance test enabled the distinction 
of patients with ADHD and NF1 from those with-
out NF1. The results showed that MOXO scores 
was signifi cantly worse in patients with NF1 than 
in controls, however the test cannot diff erentiate 
between NF1 with ADHD characteristics and 
ADHD without NF1. The test highlights sex dif-
ferences in ADHD characteristics in NF1 with im-
pulsivity and hyperactivity being more prominent 
in males than females. Over reactivity to visual 
distractors may form part of the att ention defi cit 
in NF1. Similar research with the same aim and 
yielding similar result was carried out by Lion-
François et al (13). They compared children with 
NF1 and associated ADHD symptomatology (NF1 
+ ADHD) with children diagnosed with ADHD 
without NF1. The hypothesis was that perfor-
mance diff erences in tasks of att ention between 
these two groups would be att ributable not to 
ADHD symptomatology, but to NF1 alone. Chil-
dren of both groups and the group of healthy con-
trols participated in a set of computerized tasks 
assessing intensive, selective and executive as-
pects of att ention. Children with NF1 + ADHD did 
not always perform worse than children with 
ADHD. It was concluded that ADHD symptom-
atology in NF1 does not contribute to all att ention 
defi cit, and ADHD cannot account for all att ention 
impairments in NF1.
Autistic disorder 
and neurofi bromatosis type 1
The association between NFs and autistic dis-
orders is an area of great interest for researches. 
Autism is characterised by changes in behaviour 
in all areas of the central nervous system (CNS): 
motoric, perceptual, intellectual, emotional and 
social. According to the Diagnostic and Statistical 
Manual of Mental Disorder-IV (DSM-IV) classifi -
cation and International Classifi cation of Diseas-
es-10 Edition the essential feature of autistic disor-
der is the abnormal or impaired development of 
social interactions and communication, a mark-
edly reduced repertoire of activity and interest as 
well as manifestations of disorder diff ering ac-
cording to developmental stage and chronological 
age (14). Eijk et al (15) found that the prevalence 
rate of autism spectrum disorder (ASD) in chil-
dren with NF1 was 10.9%, which is higher than in 
the general population estimated at 3-6 per 10,000 
(14). Further they concluded that the combined 
observational and screening based classifi cations 
demonstrated the highest positive predictive val-
ue for DSM-IV diagnosis, highlighting the impor-
tance of using both approaches in children with 
NF1 (15). Molosh et al (16) also indicated a higher 
incidence of ASD in NF1 patients. Recently, re-
sults of meta-analysis of social function and ASD 
in children and adults with NF1 have been pub-
lished. Findings from this analysis provide evi-
dence that children and adults with NF1 exhibit 
signifi cantly higher prevalence and severity of so-
cial dysfunction and ASD symptomatology. The 
results also support the presence of age, sex and 
comorbid ADHD as moderating factors for social 
outcomes in NF1 (17).
It is known that statins have a positive eff ect 
on the social and cognitive phenotype in animal 
knockout models. Recently a randomised con-
trolled trial of simvastatin treatment for autism in 
young children with NF 1 (SANTA) was complet-
ed (18). This trial opens a novel area by studying 
statin eff ects in younger children with NF1 and 
co-morbid autism showing feasibility of periph-
eral MAPK assay and autism symptom measure-
ment. Multiparametric imaging conducted in the 
study suggests possible simvastatin eff ects in 
brain areas previously associated with NF1 patho-
physiology and the social brain network.
Psychiatric diseases 
and neurofi bromatosis type 1
There is some question as to whether psychi-
atric and developmental disorders are over-repre-
sented in patients with NF1 particularly when pa-
tients with NF are compared to those with other 
chronic neurological disorders (19). Regarding 
this issue, Samuelsson et al conducted extensive, 
interesting and valuable research assessing gen-
eral somatic, psychiatric, social and genetic as-
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pects of NF l in a carefully defi ned population of 
residents of Gothenburg in Sweden (20-22). Thir-
ty-two of the 71 patients with NF1 (45%) showed 
slight mental retardation and two of these were 
somewhat more retarded. This slight mental retar-
dation was usually recognized during the early 
school years and it did not appear to be progres-
sive. While patients aff ected with this problem 
were placed in remedial or special classes in 
school, they generally did not require any addi-
tional vocational training. There is reason to sus-
pect that NF 1 itself leads to some impairment of 
intellectual development in all patients, for the 
intellectual achievements of those whose intelli-
gence was judged to be within the normal range 
appeared to fall short of the average. None of the 
patients with normal intelligence had passed any 
academic examination and many showed achieve-
ments less than expected based on the achieve-
ments of their healthy relatives. In certain fami-
lies, the NF appeared to be associated with mild 
mental retardation more than in other families. 
Mental retardation of a more severe degree, cor-
responding to special school level or lower, is not 
typical of NF 1 (21). Mental illness aff ected 23 
(33%) of the 69 patients with NF 1 who were in-
cluded in the study with moderately severe or se-
vere form being found in 15 of the 69 patients 
(22%). The 23 mentally ill patients did not show 
any uniform clinical psychiatric syndrome. The 
most commonly occurring psychiatric diagnoses 
were depressive syndrome, anxiety state with 
vegetative dysfunction and organic brain syn-
drome. There was a signifi cant positive relation 
between depressive syndrome and organic brain 
syndrome. Among patients with NF-1 there was a 
signifi cantly positive relation between mental ill-
ness and mental retardation, but no signifi cant 
positive relation between mental illness and phys-
ical severity of NF-1. Patients with mental illness 
also showed a signifi cantly increased frequency of 
positive neurological fi ndings indicating central 
nervous manifestations of NF-1 (22). In addition, 
the data from this study also indicated an excess 
of occupational disability, unemployment, or em-
ployment in a position characterised as not requir-
ing special skills. Only four of 69 patients studied 
were gainfully employed in positions requiring 
three to four years of vocational training (21).
Recently, great att ention is given to the asso-
ciation of postt raumatic stress disorder (PTSD) 
and various diseases particularly those with 
chronic duration. Huguen et al investigated the 
occurrence of PTSD in patients with NF (23). In 
this investigation a high level of PTSD was found 
following sporadic NF1 disclosure, especially in 
the parents of children with NF1. Bett er communi-
cation would be possible in order to minimize the 
post-traumatic stress symptoms in patients and 
their families if physicians were fully aware of the 
characteristics of this disease, its evolution and 
prognosis.
Electroconvulsive therapy (ECT) is the oldest 
form of therapy available for the treatment of se-
vere major depression. It is highly eff ective in in-
dividuals with treatment resistance and when a 
rapid response is required. Thukral-Mahajan et al. 
reported the possibility of successful use of ECT in 
patients with NF and their results confi rm the 
safety of ECT even in high-risk patients (24).
Psychotic disorders are another form of men-
tal illness that may occur simultaneously with 
NFs, however it is still not clear whether it is coin-
cidental or that a real causal connection between 
these two disorders exists (25).
Cognitive diffi  culties 
and neurofi bromatosis type 1
There is increasing research related to cogni-
tive and emotional diffi  culties as well as behav-
ioural problems in individuals with NF. Various 
components of cognitive impairment were ex-
plored in order to give a bett er insight into their 
origin and development. The eff ect of dopamine 
in these disorders has also been explored. Further 
there are att empts to include social networks in 
aiding patients and their parents to bett er under-
stand the diffi  culties and reduce their isolation 
(26-28). Results of the study concerning emotional 
and behavioural problems in children and adoles-
cents with NF 1 (26) showed that att entional prob-
lems were associated with lower verbal IQ, male 
gender, younger age and ADHD-symptoms. A 
systematic review of literature regarding behav-
iour of children and adolescents with NF1 show 
signifi cant alterations in language, reading, visuo-
spatial skills, motor function, executive function, 
att ention, behaviour, emotion and social skills.
Burgio et al (27) conducted a study aimed to 
identify the mathematical domains aff ected in 
adults with NF1 and the impact of the numerical 
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diffi  culties for patients’ daily activities. In this in-
vestigation they assessed 28 adult patients with 
NF1 and 28 healthy control participants. Obtained 
fi ndings indicate that NF1 aff ects calculation but 
not the basic comprehension or representation of 
numbers in adult patients. These data have impor-
tant implications for designing cognitive interven-
tions customised to the cognitive profi le of indi-
viduals with NF1. It was also shown that the pres-
ence of hyperintensity in magnetic brain resonance 
(NMR) fi ndings is associated with poor cognitive 
performance. Analysis of these lesions could help 
predict cognitive changes in children with NF1 
(28). Although NF1 can cause a wide range of cog-
nitive defi cits its foundation is still unknown and 
requires further investigation.
Cognitive diffi  culties and NMR changes 
in neurofi bromatosis type 1
Diff erent NMR studies have focused on neu-
roanatomical correlations between the NF1 cogni-
tive phenotype, including grey and white matt er 
volume changes (29,30), white matt er microstruc-
ture and functional connectivity changes (31,33). 
NMR fi ndings show that brain abnormalities in 
NF1 include increased white matt er volume, in-
creased subcortical grey matt er volume (e.g., thal-
amus, right caudate), decreased cortical grey mat-
ter density, T2 hyperintensities (T2H), macro-
cephaly and reduced integrity of white matt er 
microstructure (31,33-36). Thalamic T2H and vol-
ume abnormalities in the corpus callosum, puta-
men and amygdala were associated with cogni-
tive defi cits in NF1 (3,33,35). There is also a debat-
able association of these defi cits with local areas of 
T2-hyperintensities on NMR images, namely un-
identifi ed bright objects (UBOs). The study which 
included 36 children showed that the presence of 
UBOs in the thalamus and striatum may represent 
a neuroradiological patt ern that infl uences perfor-
mances in calculation and behaviour respectively 
in children with NF 1 (37).
Yoncheva et al published the results of a pilot 
study investigating the eff ect of the exercise of a 
computerized work memory program on func-
tional NMR (fNMR) measures in children with 
NF1 and working memory defi cits. Computerized 
at-home working memory training intervention 
was provided for 6–10 weeks. Investigators ob-
tained pre- and post-treatment resting-state fNMR 
and cognitive measures. Two local resting state 
measures showed regionally specifi c changes af-
ter treatment and behavioural improvement on 
untrained tasks was also observed (38).
Psychosocial skills 
and neurofi bromatosis type 1
Cipollett a et al.. conducted a study in which 
two hundred and forty participants were recruit-
ed, comprising 60 children and adolescents with 
NF1, 60 parents of children with NF1, 60 children 
and adolescents without NF1 and 60 parents of 
children without NF1. They showed that the psy-
chological functioning, behaviour, self-image and 
quality of life (QOL) of children and adolescents 
with NF1 are compromised. Individuals with NF1 
reported anxiety problems, poorer QOL and 
greater distortions in terms of self-image. When 
compared to the parents of healthy participants, 
the parents of NF1 participants reported having 
more concerns regarding the QOL, sociality, 
school performance and att ention span of their 
children. Accordingly, health services should take 
into account the psychosocial diffi  culties associat-
ed with NF1 and design rehabilitation programs 
aimed at increasing NF1 children’s interpersonal 
skills, improving their social life and QOL as well 
as promoting more adaptive behaviours. In addi-
tion, health care interventions should also involve 
the parents of children with NF1 (39).
Recent studies have documented an in-
creased risk for social problems and features of 
ASD in children with Noonan syndrome (NS), 
NF1 and related disorders. In a study investigat-
ing the social skills of children with NF1 and NS, 
participants were given well-validated caregiver 
questionnaires assessing their child’s social skills, 
language abilities, ADHD symptoms and anxiety. 
Results regarding overall social skills, average rat-
ings of children in both clinical groups were simi-
lar indicating weaker social skills. Ratings of so-
cial skills were outside of normal limits for more 
than four of the ten children within the clinical 
groups, most of the defi cits being mild or moder-
ate. Fifteen percent of the children with NS and 
5% of the children with NF1 were rated as having 
severe social skills impairment. Independent of 
diagnosis, having fewer ADHD symptoms or bet-
ter social-pragmatic language skills was predic-
tive of stronger social skills (40). Visual att ention 
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to faces within social scenes in children with NF1 
and typically developing peers was also exam-
ined. Children with NF1 spend less time att ending 
to faces than typically developing children when 
presented in social scenes. This fi ndings contrib-
ute to a growing body of evidence suggesting that 
abnormal face processing is a key aspect of the 
social-cognitive phenotype of NF1 and appears to 
be related to autism spectrum disorder traits. 
Children with NF1 demonstrated atypical gaze 
behaviour when att ending to faces and this gaze 
behaviour was characterized by normal initial fi x-
ation on faces but shorter face dwell time. De-
creased att ention to faces was associated with ele-
vated autism traits in the sample with NF1 (41).
Social problems and quality of life 
of patients with neurofi bromatosis type 1
More recently the possibilities of innovative 
applications of social media dedicated to those 
who care for children with chronic conditions can 
provide peer-to-peer support, shared experience, 
and reliable medical information was explored. 
The availability of this innovative approach can 
break their isolation, enable connection with other 
families and provide accurate information, advice 
and support from others facing similar challenges. 
The opportunity to communicate with others re-
garding the challenges they are faced with is very 
valuable and the shared experiences provide them 
with a sense of normalcy (42). Compared to unaf-
fected children and adolescents of the general 
population, paediatric patients with NF1 have an 
increased risk of having social diffi  culties, mental 
health disorders, behavioural and emotional prob-
lems as well as diminished QOL. (43).
Possibilities of medication treatment 
of behavioural impairment in patients 
with neurofi bromatosis type 1
Dopamine dysregulation has been identifi ed 
as a key modulator of behavioural impairment in 
NF1 and a potential therapeutic target. Preclinical 
research demonstrates that reduced dopamine in 
the brains of genetically engineered NF1 mouse 
strains is associated with reduced spatial-learning 
and att entional dysfunction. Methylphenidate, a 
stimulant medication that increases dopaminergic 
and noradrenergic neurotransmission, have eff ect 
on the behavioural and dopamine abnormalities. 
Although preliminary clinical trials have demon-
strated that methylphenidate is eff ective in treat-
ing ADHD symptoms in children with NF1, its 
therapeutic eff ect on cognitive performance is un-
clear. Currently an ongoing randomised, double-
blind, placebo-controlled trial to assess the effi  ca-
cy of methylphenidate for reducing att ention defi -
cits, spatial working memory impairments and 
ADHD symptoms in children with NF1 is being 
conducted (44). The results of this trial will be 
published in the near future.
CONCLUSION
The presence of a high incidence of autistic 
disorder, hyperkinetic disorder and cognitive 
problems in individuals with NFs is well known. 
Previous studies indicate the need for a multidis-
ciplinary approach to the diagnosis and treatment 
of people with NFs. The results of research re-
garding the brain changes and the possibilities of 
pharmacological therapy will improve the under-
standing of mechanisms of comorbidity develop-
ment, facilitate treatment outcome and enable the 
patients to bett er integrate into society as well as 
improve their overall QOL.
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